Advertisement

Endocrine

, Volume 59, Issue 1, pp 62–65 | Cite as

Continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin: pros and cons

  • Maria Ida Maiorino
  • Michela Petrizzo
  • Giuseppe Bellastella
  • Katherine Esposito
Pros and Cons in Endocrine Practice

Abstract

Continuous glucose monitoring associated with intensive insulin regimens represents a useful tool to lower HbA1c in selected adults with type 1 diabetes. Recent randomized controlled trials demonstrated greater glycemic benefits in type 1 diabetic patients treated with multiple daily injections of insulin and continuous glucose monitoring over usual care. These positive outcomes, however, are counter-balanced by several limitations that restrict the use of continuous glucose monitoring in the real life, including the apparent lack of benefits in children and pregnant diabetic women, the high cost, the stringent patients’ selection, and the presence of a multi-disciplinary team with specific expertise. Pros and Cons of using continuous glucose monitoring in type 1 diabetic patients with multiple daily injections of insulin are here discussed.

Keywords

Type 1 diabetes CGM Multiple daily injections Continuous subcutaneous insulin infusion 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    American Diabetes Association.: 6. Glycemic Targets Diabetes Care. 40(Suppl.1), S48–S56 (2017)Google Scholar
  2. 2.
    The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993)CrossRefGoogle Scholar
  3. 3.
    N. Mauras, L. Fox, K. Englert, R.W. Beck, Continuous glucose monitoring in type 1 diabetes. Endocrine 43, 41–50 (2013)CrossRefPubMedGoogle Scholar
  4. 4.
    A.L. Peters, A.J. Ahmann, T. Battelino, A. Evert, I.B. Hirsch, M.H. Murad, W.E. Winter, H. Wolpert, Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 3922–3937 (2016)CrossRefPubMedGoogle Scholar
  5. 5.
    W.V. Tamborlane, R.W. Beck, B.W. Bode, B. Buckingham, H.P. Chase, R. Clemons, R. Fiallo-Scharer, L.A. Fox, L.K. Gilliam, I.B. Hirsch, E.S. Huang, C. Kollman, A.J. Kowalski, L. Laffel, J.M. Lawrence, J. Lee, N. Mauras, M. O’Grady, K.J. Ruedy, M. Tansey, E. Tsalikian, S. Weinzime, D.M. Wilson, H. Wolpert, T. Wysocki, D. Xing; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Continuous glucose monitoring and intensive treatment of type 1 diabetes. N. Engl. J. Med. 359, 1464–1476 (2008)CrossRefPubMedGoogle Scholar
  6. 6.
    T. Battelino, I. Conget, B. Olsen, I. Schütz-Fuhrmann, E. Hommel, R. Hoogma, U. Schierloh, N. Sulli, J. Bolinder; SWITCH Study Group, The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 55, 3155–3162 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    R.M. Bergenstal, W.V. Tamborlane, A. Ahmann, J.B. Buse, G. Dailey, S.N. Davis, C. Joyce, T. Peoples, B.A. Perkins, J.B. Welsh, S.M. Willi, M.A. Wood; STAR 3 Study Group, Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N. Engl. J. Med. 363, 311–320 (2010)CrossRefPubMedGoogle Scholar
  8. 8.
    M.I. Maiorino, G. Bellastella, M. Petrizzo, M.R. Improta, C. Brancario, F. Castaldo, L. Olita, D. Giugliano, K. Esposito, Treatment satisfaction and glycemic control in young type 1 diabetic patients in transition from pediatric health care: CSII versus MDI. Endocrine 46, 256–262 (2014)CrossRefPubMedGoogle Scholar
  9. 9.
    M.I. Maiorino, O. Casciano, E. Della Volpe, G. Bellastella, D. Giugliano, K. Esposito, Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study. Endocrine 52, 244–252 (2016)CrossRefPubMedGoogle Scholar
  10. 10.
    N.C. Foster, K.M. Miller, W.V. Tamborlane, R.M. Bergenstal, R.W. Beck; T1D Exchange Clinic Network, Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care 39, e81–e82 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    R.W. Beck, T. Riddlesworth, K. Ruedy, A. Ahmann, R. Bergenstal, S. Haller, C. Kollman, D. Kruger, J.B. McGill, W. Polonsky, E. Toschi, H. Wolpert, D. Price; DIAMOND Study Group, Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 317, 371–378 (2017)CrossRefPubMedGoogle Scholar
  12. 12.
    M. Lind, W. Polonsky, I.B. Hirsch, T. Heise, J. Bolinder, S. Dahlqvist, E. Schwarz, A.F. Ólafsdóttir, A. Frid, H. Wedel, E. Ahlén, T. Nyström, J. Hellman, Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 317, 379–387 (2017)CrossRefPubMedGoogle Scholar
  13. 13.
    C.A. van Beers, J.H. DeVries, S.J. Kleijer, M.M. Smits, P.H. Geelhoed-Duijvestijn, M.H. Kramer, M. Diamant, F.J. Snoek, E.H. Serné, Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 4, 893–902 (2016)CrossRefPubMedGoogle Scholar
  14. 14.
    K.M. Miller, N.C. Foster, R.W. Beck, R.M. Bergenstal, S.N. DuBose, L.A. DiMeglio, D.M. Maahs, W.V. Tamborlane; T1D Exchange Clinic Network, Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. Diabetes Care 38, 971–978 (2015)CrossRefPubMedGoogle Scholar
  15. 15.
    N. Mauras, R. Beck, D. Xing, B. Buckingham, M. Tansey, N.H. White, S.A. Weinzimer, W. Tamborlane, C. Kollman; Diabetes Research in Children Network (DirecNet) Study Group, A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to\10 years. Diabetes Care 35, 204–210 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    M. Tansey, S. Weinzimer, R. Beck, K. Ruedy, P. Cheng, W. Tamborlane, C. Kollman, N. Mauras, L. Fox, J. Coffey, N.H. White; Diabetes Research in Children Network (DirecNet) Study Group, Extended 6-month follow-up of a randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to<10 years. Diabetes Care 36, e63 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    A.L. Secher, L. Ringholm, H.U. Andersen, P. Damm, E.R. Mathiesen, The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial. Diabetes Care 36, 1877–1883 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    J.C. Pickup, S.C. Freeman, A.J. Sutton, Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 7(343), d3805 (2011)CrossRefGoogle Scholar
  19. 19.
    U.S. Food and Drug Administration. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534056.htm, Accessed 16 Mar 2017

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department Medical, Surgical, Neurological, Metabolic Science and AgingUniversity of Campania “Luigi Vanvitelli”NaplesItaly
  2. 2.Diabetes UnitUniversity of Campania “Luigi Vanvitelli”NaplesItaly

Personalised recommendations